LYVE1 and prostate neoplasm: These data consistently demonstrate aberrant activation of Wnt/β-catenin signaling pathways in prostate tumor cells of R26mTmG/hAR:Osr1Cre/+ mice, implicating the regulatory role of hARtg in activating Wnt/β-catenin to promote prostate tumor development and growth.